Clinical Trial Details
— Status: Completed
Administrative data
| NCT number |
NCT05973305 |
| Other study ID # |
DORZOL-10/2015 |
| Secondary ID |
|
| Status |
Completed |
| Phase |
Phase 3
|
| First received |
|
| Last updated |
|
| Start date |
April 5, 2017 |
| Est. completion date |
September 1, 2018 |
Study information
| Verified date |
April 2023 |
| Source |
Jadran Galenski laboratorij d.d. |
| Contact |
n/a |
| Is FDA regulated |
No |
| Health authority |
|
| Study type |
Interventional
|
Clinical Trial Summary
The goal of this study is to compare efficacy and safety of Dorzol 20 mg/mL Eye Drops
manufactured by JADRAN-GALENSKI LABORATORIJ d.d. (Croatia) aimed at lowering elevated IOP in
patients with ocular hypertension and primary open-angle glaucoma (POAG) versus TRUSOPT 20
MG/ML Eye Drops manufactured by Laboratoires Merck Sharp & Dohme-Chibret, France. The main
questions it aims to answer are:
- if the efficacy of the investigational drug and the reference drug in patients with
ocular hypertension and primary open-angle glaucoma is equal;
- if the safety of the investigational drug and the reference drug in patients with ocular
hypertension and primary open-angle glaucoma is equal.
A total of 118 participants were screened and randomized 1:1 to the investigational drug
(Dorzol) group or the reference drug (Trusopt) group. 59 patients were recruited in each
group.
Researchers compared the investigational drug (Dorzol) group with the reference drug
(Trusopt) group to see if the efficacy and safety of the investigational drug and the
reference drug in patients with ocular hypertension and primary open-angle glaucoma are
equal.
Description:
Study Title:
A randomized, open-label, controlled, comparative study of efficacy and safety of Dorzol eye
drops, 20 mg/mL, manufacturer: JADRAN - GALENSKI LABORATORIJ d.d., Croatia, vs. Trusopt® eye
drops, 20 mg/mL, manufacturer: Laboratoires Merck Sharp & Dohme-Chibret, France, in patients
with primary open-angle glaucoma.
Protocol No. DORZOL-10/2015, version No. 1.0 of 25.10.2015 RCT No. 629 of 07.09.2016
Investigators
1. Abdulaeva Elmira Abdulaevna (Test facility No.4)
2. Eryomina Alyona Victorovna (Test facility No.6)
3. Lisitsyn Alexey Borisovich (Test facility No.7)
4. Doga Alexander Victorovich (Test facility No.8) Test facilities No.4. State autonomous
healthcare institution 'Republican Clinical Ophthalmological Hospital of the Ministry of
Health of the Republic of Tatarstan', 420012, Republic of Tatarstan, Kazan, Butlerova
St., 14.
No.6. Federal state autonomous institution 'Acad. S.N. Fyodorov Eye Microsurgery
Interbranch Science and Technology Complex', Ministry of Health of the Russian
Federation, 127486, Moscow, Beskudnikovsky Blvd., 59A.
No.7. State healthcare institution of Yaroslavl region 'Clinical Hospital No. 8',
150030. Yaroslavl, Suzdalskoe Highway, 39.
No.8. Federal state autonomous institution 'Acad. S.N. Fyodorov Eye Microsurgery
Interbranch Science and Technology Complex', Ministry of Health of the Russian
Federation, 127486, Moscow, Beskudnikovsky Blvd., 59A.
Study period:
First patient enrollment date: 5 April 2017 Study completion date: 1 September 2018
Phase III (a safety and efficacy study)
Study objective:
The study objective was to evaluate the efficacy and safety of Dorzol eye drops, 20
mg/mL, manufacturer: JADRAN - GALENSKI LABORATORIJ d.d., Croatia, designed to reduce
elevated intraocular pressure in patients with primary open-angle glaucoma (POAG), vs.
Trusopt® eye drops, 20 mg/mL, manufacturer: Laboratoires Merck Sharp & Dohme-Chibret,
France.
Study tasks:
- Prove noninferiority of the test vs. reference product in patients with primary
open-angle glaucoma.
- Prove that the test product is as safe as the reference product in patients with
primary open-angle glaucoma.
Study design:
A multicenter, prospective, open-label, randomized, comparative, controlled,
parallel-arm study evaluating the efficacy and safety in patients with a specific
disease.
Study subjects: 118 patients (59 subjects in each group) with elevated intraocular
pressure induced by primary open-angle glaucoma (POAG), males and females in the age
bracket of 18 to 75 years conforming to the inclusion and exclusion criteria.
Patients randomized: 118 Dropouts: 1 Per protocol population: 117 Safety population: 118
Inclusion criteria:
- Females or males in the age bracket of 18 to 75 years.
- Established stage I and II primary open-angle glaucoma in one or both eyes.
- IOP = 21-27 mm Hg (by Goldmann applanation tonometry).
- Visual acuity 0.3 or better on the tested eye.
- Patients who have signed an informed consent to participate in the study.
- For females of child-bearing potential - a negative pregnancy test and consent to
use reliable contraception methods throughout the study.
Exclusion criteria:
- Contraindications or hypersensitivity to the active ingredient (dorzolamide) or
excipients.
- The only eye.
- Visual acuity ˂ 0.3 after correction.
- An active infectious inflammatory process on the tested eye within 3 months prior
to pre-study medical examination.
- Pronounced visual field defects (III and IV stage open-angle glaucoma).
- IOP ˃ 27 mm Hg or ˂ 21 mm Hg as at the IOP measuring at 10.00 a.m. (±1 h) in any of
the eyes on the screening visit day.
- Closed or nearly closed anterior chamber angle (ACA) or history of acute angle
close.
- Surgical and laser eye interventions over the last 3 months.
- Manifest ocular media opacification hindering the treatment efficacy evaluation.
- Other eye diseases that may affect dynamics of the parameters used for the
treatment efficacy evaluation.
- Inflammatory conditions of the eye and appendages (blepharitis, conjunctivitis).
- Chronic kidney disease (creatinine clearance ˂ 30 mL/min).
- Hyperchloremic acidosis.
- Concomitant administration of oral carbonic anhydrase inhibitors.
- Children and adolescents under 18 years.
- The patient's participation in another clinical trial for the last 3 months.
- Any systemic or mental disorder/condition (unmanageable arterial hypertension,
decompensated diabetes mellitus, severe renal impairment) or clinically relevant
abnormal laboratory tests at screening that, in the Investigator's opinion, may put
a patient to a significant risk, or compromise the study results, or appreciably
affect the possibility for the patient to participate in the study.
- A patient who is unlikely to comply with the protocol requirements, e.g., is
undisposed to cooperation, and is unlikely to complete the study.
- Females and males of reproductive age refusing to use efficacious contraception
methods.
- Females during pregnancy and breastfeeding. Drug therapy type
Test product:
Trade name: Dorzol Active ingredient: dorzolamide Pharmaceutical form: eye drops Dosage:
20 mg/mL Posology and method of administration: Instillation into the conjunctival sac
of 1 drop 3 times daily for 12 weeks.
Manufacturer: JADRAN - GALENSKI LABORATORIJ d.d., Croatia
Reference product description and labeling:
Trade name: Trusopt® Active ingredient: dorzolamide Pharmaceutical form: eye drops
Dosage: 20 mg/mL Posology and method of administration: 3 times daily Manufacturer:
Laboratoires Merck Sharp & Dohme-Chibret, France Study duration: Screening: 7 days. The
comparison product treatment lasted for 12 weeks (84±2 days). Follow-up period: 7 days.
The overall study duration per patient did not exceed 99±2 days.
The efficacy is established based on analysis of the parameters as follows:
Primary endpoint
• Mean IOP change from baseline.
Secondary endpoints
- IOP reduction rate to the target level of ≤ 18 mm Hg.
- IOP reduction rate greater than 20%.
- IOP reduction rate greater than 30%. Safety evaluation
- Incidence of adverse events to a greater or lesser extent linked to the test or
reference product, including those evaluated from laboratory test findings.
- Treatment safety is evaluated from recording adverse events via analysis of
complaints and symptoms, evaluation and interpretation of the findings of
instrumental monitoring (biomicroscopy, ophthalmoscopy, IOP measures, perimetry)
and laboratory tests.
Statistical analysis Statistical analysis was performed using Statsoft Statistica
Professional 13 and Microsoft Excel 2016 software.
The Shapiro-Wilk test was used to evaluate the normality of distribution of quantitative
attributes. Parametric tests were used for testing statistical hypotheses for parameters
with the normal distribution, whereas nonparametric tests were used for parameters with
the variance of the distribution. Student's t-test and Mann-Whitney U test were used for
comparing the study groups in terms of quantitative attributes. The comparison of
intragroup parameters before and after treatment was performed using the dependent
samples t-test or the Wilcoxon test. The intragroup comparisons were also performed
using nonparametric repeated measures ANOVA (the Friedman test). Qualitative attributes
were analyzed using Pearson's χ2 test or Fisher's exact test (if the attribute incidence
rate in at least one subgroup was ≤ 5).
Statistically significant are differences with p-values < 0.05. Efficacy analysis of the
comparison products provides for a conclusion on
- Noninferiority of the test product Dorzol, eye drops (JADRAN - GALENSKI LABORATORIJ
d.d., Croatia) vs. reference product Trusopt®, eye drops (Laboratoires Merck Sharp
& Dohme-Chibret, France) by the primary endpoint:
- No statistically significant intergroup differences have been observed
regarding a mean intraocular pressure change from baseline either in the
treatment or control group (p = 0.1609; Mann-Whitney U test).
- The efficacy differences between the test and reference product by the primary
criterion do not exceed the noninferiority margin of 1.5 mm Hg.
Intergroup efficacy comparisons of the comparison products by the secondary endpoints
have also been performed, with statistical significance of intergroup differences
evaluated for ITT and PP populations:
- ITT
o No statistically significant intergroup differences have been observed regarding
the IOP reduction rate to the target level of ≤ 18 mm Hg either in the treatment or
control group (p = 0.5727; Pearson's χ2 test), which is indicative of Dorzol
noninferiority by this parameter vs. reference product.
o No statistically significant intergroup differences have been observed regarding
the IOP reduction rate greater than 20% at visit 5 from baseline at visit 1
pre-dose either in the treatment or control group (p = 0.5661; Pearson's χ2 test),
which is indicative of Dorzol noninferiority by this parameter vs. reference
product.
o No statistically significant intergroup differences have been observed regarding
the IOP reduction rate greater than 30% at visit 5 from baseline at visit 1
pre-dose either in the treatment or control group (p = 0.4524; Pearson's χ2 test),
which is indicative of Dorzol noninferiority by this parameter vs. reference
product.
- PP o No statistically significant intergroup differences have been observed
regarding the IOP reduction rate to the target level of ≤ 18 mm Hg either in the
treatment or control group (p = 0.5212; Pearson's χ2 test), which is indicative of
Dorzol noninferiority by this parameter vs. reference product.
o No statistically significant intergroup differences have been observed regarding
the IOP reduction rate greater than 20% at visit 5 from baseline at visit 1
pre-dose either in the treatment or control group (p = 0.6494; Pearson's χ2 test),
which is indicative of Dorzol noninferiority by this parameter vs. reference
product.
- No statistically significant intergroup differences have been observed
regarding the IOP reduction rate greater than 30% at visit 5 from baseline at
visit 1 pre-dose either in the treatment or control group (p = 0.4769;
Pearson's χ2 test), which is indicative of Dorzol noninferiority by this
parameter vs. reference product.
The safety evaluation provided for the conclusions as follows:
- Analysis of these AEs is indicative of comparable safety of the test product:
o AE occurrence in the treatment group does not differ reliably from AE occurrence
in the control group (p = 0.7058; Pearson's χ2 test).
o AE link to the test product was most characterized as 'probable'; there were no
statistically significant intergroup differences by this parameter either (p =
0,073).
- AE severity was most characterized as mild; there were no statistically
significant intergroup differences by this parameter either (p = 0.0863).
- Analysis of the patients' laboratory test findings has identified statistically
reliable differences by certain parameters (hemoglobin, ESR, AST, ALT, urea, total
bilirubin, total protein, urine specific gravity). However, these differences are
linked to patients' personality traits.
Thus, based on all criteria specified in the Clinical Trial Protocol, the test product
Dorzol and reference product Trusopt® demonstrate close efficacy and safety parameters.
There are no statistically significant intergroup differences by any efficacy criteria
tested. The efficacy differences between the test and reference product by the primary
criterion do not exceed the noninferiority margin of 1.5 mm Hg. The above-stated
provides for a conclusion on the test product Dorzol noninferiority vs. reference
product Trusopt®.
